Full Press Release Details
PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the following upcoming conferences:
Baird 2024 Global Healthcare Conference
Tuesday, September 10 at 12:50 PM ET
H.C. Wainwright 26th Annual Global Investment Conference
Wednesday, September 11 at 1:30 PM ET
Chardan's 8th Annual Genetic Medicines Conference
Monday, September 30 at 4:00 PM ET
The Cell & Gene Meeting on the Mesa
Monday, October 7 at 9:30 AM MST
Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts, when available, will be archived for a limited time following the event.
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.
Head of Investor Relations
SOURCE Carisma Therapeutics Inc.
21 %
more press release views with